May 11, 2020 / 12:46 PM / 18 days ago

BRIEF-Bellerophon Therapeutics Announces FDA Clears Initiation Of Phase 3 Study For Inopulse® Inhaled Nitric Oxide Therapy To Treat Covid-19

May 11 (Reuters) - Bellerophon Therapeutics Inc:

* BELLEROPHON THERAPEUTICS ANNOUNCES FDA CLEARS INITIATION OF PHASE 3 STUDY FOR INOPULSE® INHALED NITRIC OXIDE THERAPY TO TREAT COVID-19

* BELLEROPHON - FDA ACCEPTED IND APPLICATION, ALLOWING CO TO INITIATE PHASE 3 STUDY OF INOPULSE INO THERAPY IN UP TO 500 PATIENTS INFECTED WITH COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below